- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial, Adaptive Platform Trial
- Study type descriptors: Interventional
- Study aim: To assess the long-term effects of imatinib and infliximab, used during acute hospitalisation due to COVID-19-infection, on long-COVID symptoms and quality of life using questionnaires at six months, one and two years post-discharge
- Number of participants enrolled: Enrollment ongoing
- Study enrolling from to
- Study includes follow-up for 2 years
Study Data
- Hospital wide
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immnunomodulator
- Antineoplastic agent
- Imatinib
- Infliximab
- Monoclonal antibodies
External Links
Other information
Funders:
- Clinical Urology and Epidemiology Working Group
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to